These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34136717)

  • 21. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
    Lin YC; Lin JF; Wen SI; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Kaohsiung J Med Sci; 2017 May; 33(5):215-223. PubMed ID: 28433067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment.
    Jain H; Bhat AR; Dalvi H; Godugu C; Singh SB; Srivastava S
    Curr Res Pharmacol Drug Discov; 2021; 2():100041. PubMed ID: 34909670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COVID-19: Older drugs for a novel disease-Chloroquine, hydroxychloroquine, and possible Pentoxifylline-set to start the second innings?
    Thangaraju P; Gurunthalingam MP; Varthya S; Venkatesan S; Thangaraju E
    J Family Med Prim Care; 2020 May; 9(5):2172-2175. PubMed ID: 32754467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply.
    De Savi C; Hughes DL; Kvaerno L
    Org Process Res Dev; 2020 Jun; 24(6):940-976. PubMed ID: 37556267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When pathogens come in handy.
    Pastrana E
    Nat Methods; 2012 Sep; 9(9):864. PubMed ID: 23097784
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of COVID-19: a randomized controlled trial.
    Schwartz I; Boesen ME; Cerchiaro G; Doram C; Edwards BD; Ganesh A; Greenfield J; Jamieson S; Karnik V; Kenney C; Lim R; Menon BK; Mponponsuo K; Rathwell S; Ryckborst KJ; Stewart B; Yaskina M; Metz L; Richer L; Hill MD;
    CMAJ Open; 2021; 9(2):E693-E702. PubMed ID: 34145052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19.
    Manigandan S; Praveenkumar TR; Brindhadevi K
    Appl Nanosci; 2023; 13(1):111-118. PubMed ID: 34150443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk.
    Hayward G; Butler CC; Yu LM; Saville BR; Berry N; Dorward J; Gbinigie O; van Hecke O; Ogburn E; Swayze H; Bongard E; Allen J; Tonner S; Rutter H; Tonkin-Crine S; Borek A; Judge D; Grabey J; de Lusignan S; Thomas NPB; Evans PH; Andersson MI; Llewelyn M; Patel M; Hopkins S; Hobbs FDR
    BMJ Open; 2021 Jun; 11(6):e046799. PubMed ID: 34145016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to: Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
    Boglione L; Rostagno R; Poletti F; Moglia R; Bianchi B; Esposito M; Borrè S
    J Infect Chemother; 2021 Sep; 27(9):1373-1374. PubMed ID: 34158240
    [No Abstract]   [Full Text] [Related]  

  • 30. Coronaviruses, cholesterol and statins: Involvement and application for Covid-19.
    Orlowski S; Mourad JJ; Gallo A; Bruckert E
    Biochimie; 2021 Oct; 189():51-64. PubMed ID: 34153377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City.
    Lozano-Cruz OA; Jiménez JV; Olivas-Martinez A; Ortiz-Brizuela E; Cárdenas-Fragoso JL; Azamar-Llamas D; Rodríguez-Rodríguez S; Oseguera-Moguel JC; Dorantes-García J; Barrón-Magdaleno C; Cázares-Diazleal AC; Román-Montes CM; Tamez-Torres KM; Martínez-Guerra BA; Gulias-Herrero A; González-Lara MF; Ponce-de-León-Garduño A; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J
    Front Pharmacol; 2021; 12():668678. PubMed ID: 34149420
    [No Abstract]   [Full Text] [Related]  

  • 32. Potential drug development and therapeutic approaches for clinical intervention in COVID-19.
    Dowarah J; Marak BN; Yadav UCS; Singh VP
    Bioorg Chem; 2021 Sep; 114():105016. PubMed ID: 34144277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    Toxicol Sci; 2021 Aug; 183(1):227-239. PubMed ID: 34142159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials.
    Venkadapathi J; Govindarajan VK; Sekaran S; Venkatapathy S
    Front Mol Biosci; 2021; 8():637378. PubMed ID: 34179072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease.
    Yuce M; Cicek E; Inan T; Dag AB; Kurkcuoglu O; Sungur FA
    Proteins; 2021 Nov; 89(11):1425-1441. PubMed ID: 34169568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.
    Gerlovin H; Posner DC; Ho YL; Rentsch CT; Tate JP; King JT; Kurgansky KE; Danciu I; Costa L; Linares FA; Goethert ID; Jacobson DA; Freiberg MS; Begoli E; Muralidhar S; Ramoni RB; Tourassi G; Gaziano JM; Justice AC; Gagnon DR; Cho K
    Am J Epidemiol; 2021 Nov; 190(11):2405-2419. PubMed ID: 34165150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.
    Klassen SA; Senefeld JW; Senese KA; Johnson PW; Wiggins CC; Baker SE; van Helmond N; Bruno KA; Pirofski LA; Shoham S; Grossman BJ; Henderson JP; Wright RS; Fairweather D; Paneth NS; Carter RE; Casadevall A; Joyner MJ
    Front Med (Lausanne); 2021; 8():684151. PubMed ID: 34164419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR technology incorporating amplification strategies: molecular assays for nucleic acids, proteins, and small molecules.
    Feng W; Newbigging AM; Tao J; Cao Y; Peng H; Le C; Wu J; Pang B; Li J; Tyrrell DL; Zhang H; Le XC
    Chem Sci; 2021 Mar; 12(13):4683-4698. PubMed ID: 34163728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Micronutrient therapy and effective immune response: a promising approach for management of COVID-19.
    Lotfi F; Akbarzadeh-Khiavi M; Lotfi Z; Rahbarnia L; Safary A; Zarredar H; Baghbanzadeh A; Naghili B; Baradaran B
    Infection; 2021 Dec; 49(6):1133-1147. PubMed ID: 34160789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in antibody-based immunotherapy strategies for COVID-19.
    Esmaeilzadeh A; Rostami S; Yeganeh PM; Tahmasebi S; Ahmadi M
    J Cell Biochem; 2021 Oct; 122(10):1389-1412. PubMed ID: 34160093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.